INS and obesity disorder: Given that effects of SGLT2i mimics catabolic state such as the increase of fat oxidation, ketone production and glucagon/insulin ratio, the administration of SGLT2i could be expected to enhance catabolic response during night and to restore dysregulated metabolic rhythm in obesity or T2DM patients.